> ## Content Index
> Fetch the complete content index at: https://www.purevalueideas.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Research #1
- URL: https://www.purevalueideas.com/research-1/
- Published: 2026-10-21T06:58:38.000Z
- Updated: 2026-10-22T00:17:02.000Z
- Author: Pure Value Ideas

# GE HealthCare: The Former Conglomerate's Lone Laggard

Pure Value Ideas - Research Post #1 · Oct 20, 2026 ·

In November 2021, General Electric said it would split into three public companies. GE HealthCare went first, on 3 January 2023\. GE Vernova, the energy business, followed on 2 April 2024, and what was left became GE Aerospace. Larry Culp ran the break-up as GE's chief executive. He now runs GE Aerospace and chairs GE HealthCare's board.

GE HealthCare is the only laggard of the three. GE Aerospace has taken its adjusted operating margin from 17.4% in 2023 to 21.3% over the twelve months to September 2026, and its free cash flow from $4.7B to $8.5B. Its commercial engines earn about 26%, well ahead of Rolls-Royce and Pratt & Whitney. GE Vernova was the weakest piece at separation. Over the twelve months to June its adjusted EBITDA margin reached 9.9%, up from 2.4%, and it generated $12.4B of free cash flow, much of it from working capital. Its power unit, which makes the gas turbines, lifted its margin from 7.0% to 14.2%, close to Siemens Energy's gas business at 14.6% and Mitsubishi Heavy's energy unit at 14.3%. Gas turbine orders more than tripled between 2023 and 2025, to 29.8 gigawatts. GE HealthCare hasn't kept up. It earned a 15.1% adjusted EBIT margin in its first year on its own and 14.8% over the twelve months to June, and its free cash flow slipped from $1.7B to $1.6B.

![](https://storage.ghost.io/c/48/60/4860aa23-9b17-4cca-9618-d0d2ab8af9fb/content/images/2026/10/image1-3.png)

Adjusted margin and free cash flow of the three GE companies, FY2023 to the latest twelve months (to Sep 2026 for GE Aerospace, Jun 2026 for the others), from company results releases

GEHC trails its own industry too. GE's jet-engine business sets the pace in its industry, while in imaging GEHC is the one catching up. Against Siemens Healthineers and Philips, the problem is product. For years GEHC spent less on research than either rival, and it got to the newest scanner platforms years late. Siemens has sold photon-counting CT since 2021, and GEHC's first system was cleared by the FDA in March 2026\. Philips launched helium-light MRI in 2018\. GEHC's arrived in February 2026.

The turnaround now under way has four chapters:

1. Heartbeat, a lean business system introduced in 2025, is meant to fix how the company runs.
2. A wave of launches, paid for by an R&D budget raised since the spin-off.
3. SOFIE builds on the one place GEHC already leads. It's the only company that makes every major kind of scanner and every class of imaging drug.
4. A decision on Patient Care, due by February 2027, could leave a smaller, more focused company.

## How GEHC fell behind

GEHC trailed Siemens on all three new scanner platforms of the past decade, and Philips on helium-light MRI. Imaging is won platform by platform. Whoever ships a new generation first wins the academic centers everyone else visits, and those sites set the replacement cycle for a decade.

![](https://storage.ghost.io/c/48/60/4860aa23-9b17-4cca-9618-d0d2ab8af9fb/content/images/2026/10/image2-7.png)

First FDA clearance by platform and company; GEHC's total-body PET has a CE mark only

The lag goes back to spending. Every year since 2019, GEHC has spent a smaller share of revenue on R&D than any of its four main rivals. In 2021, its last full year inside General Electric, it spent 4.6%. Siemens Healthineers spent 8.6%, Mindray 10.0%, Philips 10.5% and United Imaging 13.3%.

![](https://storage.ghost.io/c/48/60/4860aa23-9b17-4cca-9618-d0d2ab8af9fb/content/images/2026/10/image3-4.png)

R&D expense as a share of revenue: GE HealthCare, Siemens Healthineers, Philips (group), United Imaging and Mindray, 2019–2025

GEHC plans on a major new platform only every five to seven years, so today's gaps were set by budgets from the late 2010s. Independence changed that. The spin-off filing promised to "accelerate investments in R&D", and spending rose from $816M in 2021 to $1,311M in 2024, or 6.7% of revenue. It dipped to $1,260M in 2025 as some programs reached production and their costs moved into cost of revenue. GEHC's own broader measure adds engineering costs booked in cost of revenue, and on that basis it spent 8.5% of revenue in 2025 and more than $5.1B since the spin. Even that only matches Siemens' narrower R&D line. It still trails Philips, Mindray and United Imaging.

GEHC's technical know-how holds up. It won FDA clearance for deep-learning CT image reconstruction in April 2019, almost three years ahead of Philips. Flyrcado, approved in September 2024, is the only FDA-approved fluorine-18 PET tracer for imaging blood flow to the heart. The lag is in the hardware.

Jet engines offer an example of each outcome. Pratt & Whitney's adjusted margin was about 8.5% over the latest twelve months, excluding a one-off tariff recovery, and it's still paying for a new engine that reached the market with durability problems. Rolls-Royce lifted its civil margin from 16.6% to 20.5% in one year, on a transformation program run from the top. Like Pratt's, GEHC's problem is product. But the fix has to follow Rolls-Royce's route, getting operating discipline in place first and better products to sell after that.

## The field

Four companies stand between GEHC and the top of its markets. Two are the other Western incumbents, Siemens Healthineers and Philips, which compete across the imaging line. The other two are Chinese challengers. United Imaging makes a full imaging line; Mindray is strongest in patient monitoring and ultrasound.

Put the five imaging businesses side by side and one incumbent, Siemens, has clearly pulled ahead over the past six years.

![](https://storage.ghost.io/c/48/60/4860aa23-9b17-4cca-9618-d0d2ab8af9fb/content/images/2026/10/image4-7.png)

Imaging revenue of the five companies, 2019–2025 at 2025 average exchange rates ($1.13 per euro, RMB7.19 per dollar); first halves at each half's average rates (Federal Reserve G.5A and H.10). Siemens Healthineers external revenue, fiscal years to September, first half of 2026 estimated from its new segments; Philips 2019–2020 exclude an estimated €810M for informatics; Mindray 2019–2022 estimated at its 2023 ratio of imaging excluding animal medical.

At constant 2025 exchange rates, the five sold $43.7B of imaging equipment and service in 2025, up from $33.1B in 2019\. Siemens Healthineers' share rose from 35.0% to 38.3%, and United Imaging's from 1.3% to 4.4%. GEHC slipped from 35.9% to 33.4%, and Philips from 26.2% to 22.1%. In 2019 GEHC's imaging business was slightly bigger than Siemens'. By 2025 Siemens' was $2.1B bigger.

### Siemens Healthineers: the benchmark

Siemens Healthineers is the industry's gold standard. Its imaging and interventional businesses grew from €10.2B of external sales in fiscal 2019 to €14.8B in fiscal 2025\. That's 6.3% a year in euros, against GEHC's 3.5% in dollars. Its Imaging segment earned an adjusted EBIT margin of 20% to 22% every year from 2019 to 2025\. In the first nine months of fiscal 2026 it earned 23.6% on a new, narrower segment basis, or 21.9% without a tariff refund. GEHC's combined imaging and ultrasound margin was 14.2% over the twelve months to June. Siemens outspends GEHC in absolute terms too: €1.95B of R&D over the twelve months to June, about $2.3B, against GEHC's $1.28B. That total does also fund Siemens' diagnostics and radiotherapy arms.

The spending shows up in Siemens' platforms. Its NAEOTOM Alpha photon-counting CT, cleared in September 2021, had more than 200 systems installed by mid-2025 and now makes up about 30% of its CT order volume. Cheaper Pro and Prime versions were cleared in 2025 and are now sold in China. Its DryCool helium-light magnets started in a low-field scanner in 2021 and reached the 1.5-tesla line in 2025\. Every second MRI ordered from Siemens in April–June 2026 used one. Its PETNET tracer network is expected to pass $1B of revenue in fiscal 2026\. And Varian, bought in 2021, gives it what it calls the global No.1 position in radiation therapy, a market GEHC reaches only through a partnership with Elekta.

Siemens has its own distractions. Its laboratory diagnostics business is shrinking under Chinese price pressure and is being readied for a carve-out. Siemens AG plans to spin off part of its roughly 67% stake, with a shareholder vote in February 2027\. Net debt is about €12B, 2.8 times EBITDA. Since fiscal 2026 it has reported in new segments, splitting diagnostic imaging from a precision-therapy unit that houses Varian, interventional systems and ultrasound. In October it stopped selling general-imaging ultrasound to concentrate on ultrasound used in cardiac procedures. A week later GEHC launched a new general-imaging system, LOGIQ Focus. Siemens' imaging business has kept growing through all of this. Still, the reorganization is GEHC's best chance to gain on Siemens.

### Philips, whose products outrun its execution

Philips is the reason GEHC isn't last on every measure. Its Diagnosis & Treatment businesses grew only 1.8% a year in euros from 2019 to 2025\. Their share of the five companies' imaging revenue fell from 26.2% to 22.1%, the biggest loss in the group. The segment's adjusted EBITA margin fell from 13.1% in 2021 to about 10.8% over the twelve months to June, excluding a tariff refund (11.9% with it). In April–June 2026 alone it was 9.3% before the refund.

Most of the damage happened outside imaging. In June 2021 Philips recalled Respironics sleep-apnea and ventilator devices. Under a U.S. consent decree signed in April 2024, it can't sell new sleep-apnea machines in the U.S. until it meets FDA requirements. In 2025 it paid about $1.1B to settle personal-injury and medical-monitoring claims, and Justice Department criminal and civil investigations are still open. Its R&D spending fell from €1.89B in 2023 to €1.70B in 2025, or 9.5% of sales, just as GEHC was raising its broader innovation spending.

Philips still beats GEHC on product in several places. Its BlueSeal helium-light MRI reached the market in 2018 and had more than 2,000 installations by March 2026\. It estimates it holds about 46% of the world market for image-guided therapy systems and 47% of cardiovascular ultrasound. It has more than 800 spectral CT systems in use but no photon-counting product. In February 2026 it said only that it's "primed" for one. Chief executive Roy Jakobs is targeting mid-single-digit sales growth and a mid-teens margin by 2028\. If he gets there, GEHC loses its cushion in the rankings.

### United Imaging: the full-line challenger

United Imaging is the only Chinese company selling CT, MRI, PET, X-ray and radiotherapy systems. Revenue rose from RMB3.0B in 2019 to RMB13.8B in 2025, about $1.9B. That's 29% a year compounded, and it reached RMB14.8B over the twelve months to June. Nobody in this group spends more of its revenue on R&D, at 13–19% a year.

That spending has got it to market first more than once. The FDA cleared its uEXPLORER total-body PET scanner in December 2018, more than two years before Siemens' long-axial system; GEHC still hasn't won FDA clearance for one. United Imaging won FDA clearance for a 5-tesla whole-body MRI in April 2024\. In August 2025 China approved its uCT Ultima, the country's first domestically made photon-counting CT, seven months before GEHC's Photonova won FDA clearance.

At home, United Imaging says third-party data rank it first in China by value of new installations across its product lines (excluding ultrasound), and first in PET/CT for ten years running. China's 2024 slowdown still hurt. Revenue fell 10% that year, then rebounded 34% in 2025.

Now the growth is abroad. Overseas sales went from RMB99M in 2019 to RMB3.4B in 2025, about a quarter of revenue, and grew 54.5% in the first half of 2026\. The U.S. is still small, about 6% of sales in that half, served partly from a Houston plant whose capacity it tripled in 2025\. Its U.S. product catalog is already big, though. It holds 88 FDA 510(k) clearances, 26 of them since the start of 2025\. Channel checks describe it pricing comparable systems 20–25% below the incumbents and bundling years of service into European tenders.

### Mindray: the monitoring challenger

Mindray competes with GEHC in two places: patient monitoring and anesthesia, against Patient Care, and ultrasound, against the imaging unit. And its strongest businesses happen to be GEHC's weakest. Frost & Sullivan data in Mindray's 2026 Hong Kong listing filing put it first in the global patient-monitoring and life-support market in 2024, with 14.3%. Just behind, at 13.9%, is an unnamed U.S. peer whose description matches GEHC. The same study ranks Mindray second worldwide in patient monitors and third in anesthesia and in ultrasound, and first in China in all three.

Like United Imaging, Mindray is growing abroad while China shrinks. International revenue rose from RMB7.0B in 2019 to RMB17.7B in 2025, 53% of the total. In 2025 a weak Chinese hospital market cut its domestic sales by 23%, its monitoring and life-support revenue by about 20% and total revenue by 9%. Outside China its monitoring business grew more than 10% in the first half of 2026\. GEHC's Patient Care revenue fell 13.5% organically in the second quarter. Mindray says it now covers about 80% of U.S. integrated delivery networks, and it counts 17 of the world's top 100 hospitals among its international accounts.

It spends about 10% of revenue on R&D, more than GEHC does, and since 2021 it has cleared its newest monitors, anesthesia machines and premium ultrasound with the FDA. Its top-end Resona A20 ultrasound, cleared in November 2024, launched in North America in December 2025.

### Technology scorecard

Siemens leads or shares the lead on most hardware platforms. GEHC leads on imaging drugs and AI-enabled devices, and it's catching up on the rest.

| Platform                            | GE HealthCare                                              | Siemens Healthineers                                                     | Philips                                       | United Imaging                                   | Mindray                                           |
| ----------------------------------- | ---------------------------------------------------------- | ------------------------------------------------------------------------ | --------------------------------------------- | ------------------------------------------------ | ------------------------------------------------- |
| Photon-counting CT                  | FDA Mar 2026; ships early 2027                             | FDA Sep 2021; 200+ installed by mid-2025; \~30% of CT orders             | None; 800+ spectral CT systems                | China approval Aug 2025; no FDA filing disclosed | No CT                                             |
| Helium-light MRI                    | 1.5T, FDA Feb 2026                                         | 0.55T FDA Jul 2021; 1.5T Jun 2025; half of MRI orders                    | 1.5T, FDA Aug 2018; 2,000+ installed          | Not disclosed                                    | No MRI                                            |
| Total-body PET                      | CE mark Nov 2025; not FDA-cleared                          | FDA Mar 2021                                                             | No long-axial system                          | FDA Dec 2018                                     | No PET                                            |
| Interventional (IGT)                | Allia; Pulse FDA Oct 2023                                  | ARTIS; six systems cleared Apr 2026                                      | Azurion; \~46% world share (company estimate) | uAngio AVIVA CX, FDA Apr 2025                    | No IGT                                            |
| Ultrasound                          | Vivid Pioneer, FDA Jul 2025; LOGIQ Focus launched Oct 2026 | Procedural only (ACUSON Origin, P500 ICE); left general imaging Oct 2026 | No.1 cardiovascular, \~47% share (company)    | uSONIQUE, FDA May 2026                           | No.3 globally; Resona A20, FDA Nov 2024           |
| Patient monitoring                  | Under review; Q2 2026 revenue −13.5%                       | Not in market                                                            | Claims No.1                                   | Not in market                                    | No.1 in monitoring and life support, 14.3% (2024) |
| Radiotherapy                        | Elekta partnership; MIM software                           | Varian, "global No.1" (company)                                          | Not in market                                 | Linacs; RMB591M of 2025 sales                    | Not in market                                     |
| Imaging drugs                       | Contrast, PET and SPECT tracers, cyclotrons; SOFIE pending | PET tracers (PETNET, $1B+ in FY2026)                                     | None                                          | None                                             | None                                              |
| FDA AI-enabled devices, to Jun 2026 | 109                                                        | 96                                                                       | 49                                            | 45                                               | 1                                                 |

## How the economics compare

How each of the five makes money explains GEHC's problem and the challengers' threat.

![](https://storage.ghost.io/c/48/60/4860aa23-9b17-4cca-9618-d0d2ab8af9fb/content/images/2026/10/image5-4.png)

Share of revenue by use over the twelve months to June 2026 (Siemens Healthineers July–June): R&D, cost of sales, selling/admin/other (the remainder) and reported operating profit, from company filings

GEHC puts less of each sale into R&D than any rival: 6.0%, against 8.4% to 14.1%. The Chinese pair keep more of each sale after the cost of making it, even though they sell for less. United Imaging's gross margin is 46.7% and Mindray's 59.9%, against 39.0% to 45.9% for the Western three. Neither filing explains the gap; a domestic supply chain and lower labor costs are the likely reasons. On reported operating margin, GEHC's 12.9% is a point behind Siemens' 13.9%, and both include one-time tariff refunds booked this year. The real gap between those two is in R&D and cash, and it widens on the adjusted figures each company prefers.

### Margins, mix and exposure

The Chinese pair are giving up gross margin as they push abroad, and all five depend less on China than they did in 2021.

| Measure                                 | GE HealthCare          | Siemens Healthineers | Philips                | United Imaging                  | Mindray                                 |
| --------------------------------------- | ---------------------- | -------------------- | ---------------------- | ------------------------------- | --------------------------------------- |
| Company-adjusted margin, TTM            | 14.8% adj. EBIT        | 16.6% adj. EBIT      | 13.4% adj. EBITA       | Not reported                    | Not reported                            |
| Gross margin, FY2021 → TTM              | 40.8% → 39.5%          | 38.6% → 39.0%        | 41.8% → 45.9%          | 49.4% → 46.7%\*                 | 65.0% → 59.9%\*                         |
| Service share of revenue, FY2021 → TTM  | 36.5% → 34.0%          | Not disclosed        | 25.5% → 27.7% (FY2025) | 6.1% → 12.6%                    | About 2%                                |
| Service gross margin, TTM               | 51.0% (products 33.6%) | Not disclosed        | Not disclosed          | 61.9% (equipment 46.6%), FY2025 | Not disclosed                           |
| China share of revenue, FY2021 → FY2025 | 14.3% → 9.8%           | 13.1% → 10.6%        | 8.2% → 6.7%            | About 93% → 74%                 | 60.4% → 47.0%                           |
| U.S. share of revenue, FY2025           | 44.5%                  | 38.1%                | 40.0%                  | About 6% (1H2026)               | Not disclosed                           |
| Service workforce                       | 8,900 field engineers  | Not disclosed        | Not disclosed          | 1,000+ engineers                | 13,000+ certified service professionals |

\*Mindray and United Imaging moved warranty costs into cost of sales from 2024, so part of their decline is accounting. Siemens Healthineers' and Philips' adjusted margins include tariff refunds booked in April–June 2026, worth about 0.9 and 1.0 points; GEHC's adjusted EBIT excludes most of its refunds. Philips figures include Personal Health, and its country shares are by seller location. United Imaging's China share is its domestic revenue.

### Equipment pricing: GEHC already sells at a discount

Public tender awards show what hospitals actually pay. We pooled 225 of them from 2023 to 2026, taken from official procurement portals in 17 countries: China's Zhejiang and Shanghai networks, Brazil's federal purchasing data, Italy's Consip, the EU tender database, U.S. federal orders, U.K. contract notices, Indonesia's health ministry, Japan's procurement records, Ukraine's Prozorro and Colombia's SECOP. All prices are in dollars at the award month's exchange rate, with Chinese and Japanese VAT removed.

![](https://storage.ghost.io/c/48/60/4860aa23-9b17-4cca-9618-d0d2ab8af9fb/content/images/2026/10/image6-5.png)

Pure Value compilation of 225 public tender prices, 2023–2026, from the official portals listed under Sources; one point per tender, brand and class; research purchases excluded. Classes: 3-tesla and 1.5-tesla MRI; premium CT (256 rows or more, 16 cm, dual-source or detector-spectral); mid-range CT (64–160 slices).

GEHC's average price is 10–18% below Siemens' in each of the four main classes. Within the same country and class, it averages 94% of Siemens' price. United Imaging's discounts are a home-market tactic. In China its 3-tesla MRI averaged $1.8M, about a fifth below Siemens' $2.3M, and its premium CT $1.4M against $1.7M. In Italy's 3-tesla MRI tender and in Brazil, it bid above Siemens. Siemens' photon-counting CT averaged $2.8M, a price tier of its own.

Italy's national framework is the cleanest like-for-like test. In November 2024 Consip had GE, Siemens, Philips, Canon and United Imaging bid on one fixed specification for 3-tesla MRI and one for premium CT. Each price included installation and 24 months of full-risk service, and the bids were scored 70% on technical merit and 30% on price.

![](https://storage.ghost.io/c/48/60/4860aa23-9b17-4cca-9618-d0d2ab8af9fb/content/images/2026/10/image7-8.png)

Consip tenders ID 2785 (3-tesla MRI) and ID 2784 (CT for advanced applications), Lot 1 purchase: unit prices from each supplier's economic offer in its signed framework agreement; ranking from Consip's award listings and notices, Sep 2025; ceilings from the tender rules.

In MRI, GEHC bid $1.29M, the same as Siemens and $26,000 below Philips, and still finished third behind both. Its bid was cheaper than Philips', so its technical score must have been lower. CT flipped the order. GEHC's Revolution Apex Elite ranked first and beat Canon's cheaper scanner, but GEHC bid 39% below the ceiling, while Siemens bid 2% below and finished fourth. United Imaging bid the most in MRI and ranked last in both. The biggest single tender shows the same habit. In Indonesia's 2025 national order for more than 300 CT scanners, GEHC won with a bid about 20% below Philips' and about half of Siemens'.

GEHC already sells below Siemens in most markets, so it has little room left to meet a challenger on price. In Italy, even matching Siemens' 3-tesla price wasn't enough to finish ahead of Philips. It can win in CT, but in Italy and Indonesia it did so with the lowest Western bid. Its China-made scanners show it can match the challengers at the entry level.

### Service: the edge the challengers are still building

The incumbents' biggest advantage comes after the sale. GEHC earned $7.2B from services over the twelve months to June, a third of its revenue, at a 51.0% gross margin against 33.6% on products. Behind that is an installed base GEHC put at more than 4 million devices at its spin-off, and 8,900 field service engineers. Philips earned 27.7% of group sales from services in 2025\. Siemens doesn't split its revenue, but it describes a substantial part as recurring and carries a €36B order backlog.

United Imaging is building the same model from a much smaller base. Service rose from 5.5% of sales in 2019 to 12.4% in 2025, and to 12.6% over the twelve months to June. In 2025 it earned a 61.9% gross margin, well above the 46.6% on equipment. The installed base is about 39,000 systems, only 4,500 of them outside China and about 640 in the U.S., supported by around 1,000 engineers. Mindray earns little from service directly, about 2% of revenue, but recurring reagents and consumables made up about 40% of its 2025 sales.

So bundled service is the challengers' most effective tactic. Folding years of maintenance into the equipment price, as channel checks describe United Imaging doing in European tenders, goes straight at the incumbents' highest-margin revenue. It's also why GEHC's installed base buys it time. Every scanner already in place is a service contract, and a replacement order a challenger has to win away.

## Chapter one: Heartbeat

The first fix is how the company runs. GEHC calls Heartbeat its "lean business system". Rolled out in mid-2025, it runs the company on five measures: safety, quality, delivery, cost and innovation. GEHC links it to a better customer experience, and expects it to bring higher productivity and wider margins. The chair, Larry Culp, led GE's own lean transformation, and the board tracks Heartbeat's rollout directly.

This year has shown what it has to fix. Supply broke first, with Patient Care losing money in the second quarter on parts shortages and end-of-life components. Pricing is lagging costs. GEHC expects about $250M of input-cost inflation in 2026, with price increases catching up only in the second half, and it cut guidance in April. Cash is the weakest point. Free cash flow was 7.4% of revenue over the twelve months to June, and the 2026 guide needs \~$1.42B in the second half alone.

GEHC hasn't published any Heartbeat-specific results yet, so the next few quarters are its first public test. The people around it point the same way. Bill Grogan came in as CFO in September from Xylem, and AT&T's outgoing CFO joins the board in January. Trian built a \~0.7% stake in the second quarter.

## Chapter two: catching up on product

The second fix is what GEHC sells, and the bigger R&D budget is starting to show. In 2025, 55% of product revenue in imaging and Patient Care came from products launched in the past three years, up about five points in a year. At its November 2024 Investor Day, GEHC targeted more than 25 new imaging products through 2028.

The two platform catch-ups land in 2027\. Photonova Spectra, the photon-counting CT, is cleared in the U.S. and Europe. Management says its pipeline passed $100M in June, with most shipments starting in early 2027\. The Freelium MRI arrives just as helium supply has tightened, which makes a sealed magnet easier to sell. And management says new products launch at higher prices and lower build costs than the ones they replace.

Orders are already moving, and the new platforms haven't even shipped. They rose a record 11.1% organically in the second quarter of 2026\. Management says new products made up less than a fifth of that growth.

Catching up still leaves GEHC second. Siemens' photon-counting systems were about 30% of its CT orders in April–June 2026, and it has five years of reference sites. The realistic goal is a credible second place at the top of the market, with GEHC's lead in workflow software and AI as the difference. It has more entries on the FDA's list of AI-enabled devices than any rival: 109, against 96 for Siemens and 49 for Philips.

Intelerad, bought in March, is GEHC's biggest bet on that software lead. GEHC paid $2.3B in cash, partly borrowed, for a company that sells cloud image archiving, viewing and reporting software by subscription. It has more than 1,500 healthcare customers and a strong position in outpatient imaging. GEHC expects about $270M of revenue in the first full year, growing at a low double-digit rate. About 90% of it is recurring, at an adjusted EBITDA margin above 30%. Acquired businesses, mainly Intelerad, added $62M of imaging revenue in the second quarter, close to that pace. At about 8.5 times revenue, it wasn't cheap. GEHC expects the deal to dilute adjusted EPS slightly at first and to reach a high-single-digit return on invested capital only by year five. It's also the main reason net debt has risen to about 2.5 times EBITDA.

## Chapter three: the integrated moat

GEHC already leads on breadth. It's the only company that makes every major kind of scanner and every class of imaging drug: CT, MRI, PET, SPECT and ultrasound systems; X-ray, MRI and ultrasound contrast agents; PET and SPECT tracers; and the cyclotrons and chemistry systems that produce PET tracers. Its imaging drugs were used in 140 million procedures in 2025, about four every second. No other scanner maker sells contrast media, and no drug maker sells scanners. Pharmaceutical Diagnostics earned a 28.6% segment margin on $3.15B of revenue over the twelve months to June, and grew 14.6% organically in the second quarter.

![](https://storage.ghost.io/c/48/60/4860aa23-9b17-4cca-9618-d0d2ab8af9fb/content/images/2026/10/image8-7.png)

GEHC, Siemens Healthineers, Philips, Lantheus, Telix and Cardinal Health filings; Bayer and Guerbet 2025 annual reports; United Imaging and Canon 2025 annual reports; Bracco and Curium product pages, October 2026

Each of the closest rivals has part of the picture. Siemens Healthineers matches GEHC on scanners, cyclotrons and PET tracers, but sells no contrast or SPECT tracers. Bracco covers every class of contrast, PET and SPECT tracers and its own injectors, but makes no scanners. Bayer pairs contrast with its MEDRAD injectors, whose Stellant CT systems alone sold €583M in 2025, and it owns an approved cancer therapy, Xofigo. It has no scanners or marketed tracers.

GEHC says the combination "enables building capabilities across disease states", and its newest products are built that way. Cardiology is the clearest case: GEHC sells Flyrcado, a PET tracer for heart scans, alongside its Omni Legend PET/CT, which has passed 500 installations. Alzheimer's is another. The new antibody drugs need amyloid confirmation, usually by PET scan or spinal fluid test, and MRI monitoring, and GEHC sells the Vizamyl tracer, both kinds of scanner and MIMneuro analysis software. For cancer treatment with radioactive drugs, it offers cyclotrons, the StarGuide SPECT/CT scanner and MIM's dosimetry software.

Breadth doesn't lock customers in. GEHC's own 10-K says its agents work with other vendors' systems, and a hospital doesn't need a GE scanner to use Omnipaque. Rivals also go deeper in places. GEHC's contrast injectors are made by other manufacturers, while Bayer, Bracco and Guerbet sell their own.

SOFIE builds on its best performing business. For $945M in cash, with closing in the first half of 2027, GEHC gets 15 U.S. manufacturing sites with 21 cyclotrons, a theranostics manufacturing site and the U.S. rights to FAPI-74, a cancer-imaging tracer in Phase III. GEHC calls it a footprint in the "final mile" of U.S. PET supply. PET tracers decay within hours, so whoever makes them near the hospital controls availability. Even with SOFIE, GEHC's U.S. network will be about a third the size of Siemens'. And SOFIE also makes tracers for other companies under contract.

SOFIE already makes Flyrcado, GEHC's cardiac PET tracer. Weekly doses reached 545 in late July, about 40% above April, management said, and it still targets $500M or more of revenue by 2028\. Analysts put the annualized run-rate near $50M. CMS has proposed paying more for cardiac PET scans from 2027.

### How the drug business compares

In imaging drugs GEHC faces a different set of rivals. Bayer and Bracco, its main competitors in contrast media, don't publish margins for those businesses. The listed specialists are Lantheus and Telix in PET tracers, Guerbet in contrast media, and China Isotope & Radiation, China's state-owned radiopharmaceutical supplier. The field is consolidating. In August Curium, a privately owned radiopharmaceutical maker, agreed to buy Lantheus for up to $8.0B, or $102.50 a share in cash plus up to $12 in milestone payments, with closing expected in the first half of 2027\. Lantheus shareholders approved the deal on 14 October; it still needs U.S. antitrust clearance. In September Telix agreed to buy ITM, a German radiopharmaceutical developer, for $1.65B upfront.

![](https://storage.ghost.io/c/48/60/4860aa23-9b17-4cca-9618-d0d2ab8af9fb/content/images/2026/10/image9-3.png)

Twelve months to June 2026 from FY2025 annual reports and 2026 interim filings: GEHC Pharmaceutical Diagnostics segment, Lantheus, Telix, Guerbet, China Isotope & Radiation. Euro and yuan converted at ECB monthly averages, July 2025–June 2026.

Pharmaceutical Diagnostics is the largest of the five and the only one that sells both X-ray and MRI contrast and radioactive tracers. Its segment margin was 28.6% over the twelve months to June, down from 34.3% in 2021\. It grew 15.6% in 2025, or 8.8% organically, which excludes Nihon Medi-Physics, the Japanese tracer maker it took full control of in March 2025\. The peers show the alternatives. Lantheus keeps more of each sale, with a 60.1% gross margin and a 34.0% adjusted operating margin, but 62% of its revenue comes from one PET tracer, Pylarify, whose sales fell 6.5% in 2025 as its price dropped. Telix grew 56% in 2025, helped by an acquisition. It spends 24% of revenue on R&D, and its 7.4% operating margin includes a one-off $40M upfront payment from Regeneron. Guerbet, the closest contrast-only peer, shrank 6.5% in 2025\. It has lost money since compliance problems at its plant in Raleigh, North Carolina, forced an €86M impairment.

Three of the four specialists depend on one market, and two carry heavy debt.

| Measure                                | GE HealthCare PDx                     | Lantheus                   | Telix                  | Guerbet                              | China Isotope & Radiation |
| -------------------------------------- | ------------------------------------- | -------------------------- | ---------------------- | ------------------------------------ | ------------------------- |
| Revenue, TTM                           | $3,150M                               | $1,556M                    | $891M                  | €778M                                | RMB7,314M                 |
| Revenue growth, FY2025                 | +15.6% (organic +8.8%)                | +0.5%                      | +56%\*                 | −6.5%                                | −5.1%                     |
| Company-adjusted margin, TTM           | 28.6% segment EBIT                    | 34.0% adj. operating       | 7.9% adj. EBITDA       | 8.6% EBITDA                          | Not reported              |
| Gross margin, FY2021 → TTM             | 48.7% (FY2022) → 48.8%                | 44.1% → 60.1%              | 59.3% (FY2022) → 53.7% | Not reported                         | 63.0% → 49.5%             |
| Largest products, FY2025               | Contrast media and tracers, not split | Pylarify 64%, Definity 21% | PSMA PET tracers 77%   | X-ray contrast 54%, MRI contrast 32% | Nuclear medicines 56%     |
| U.S. share of revenue, FY2025          | Not disclosed (GEHC 44.5%)            | 94.6%                      | 97.7%                  | Americas 29.7%                       | None                      |
| China or Asia share, FY2025            | Not disclosed (GEHC China 9.8%)       | Rest of world 5.4%         | China 1.2%             | Asia 26.5%                           | All in China              |
| Net debt / EBITDA, 30 June 2026        | 2.5x (whole GEHC)                     | 0.1x                       | 3.7x                   | 11.7x                                | 0.3x                      |
| Credit ratings (Moody's / S&P / Fitch) | Baa2 / BBB / BBB (whole GEHC)         | None disclosed             | None disclosed         | None disclosed                       | None disclosed            |

\*Includes Telix's 2025 acquisition of RLS, a U.S. radiopharmacy network. TTM is the twelve months to 30 June 2026\. Net debt at 30 June includes leases and bonds, with convertibles at carrying value; EBITDA is twelve-month operating income plus depreciation, amortization and impairment, unadjusted, on the same basis for all five. GEHC's rose with the debt for its $2.3B Intelerad purchase. Guerbet's own measure, which also adds back provisions, is 5.3x; it failed its loan covenant test at 30 June and obtained waivers afterwards.

Public price lists show where GEHC competes on price and where it charges more.

![](https://storage.ghost.io/c/48/60/4860aa23-9b17-4cca-9618-d0d2ab8af9fb/content/images/2026/10/image10-3.png)

VA Federal Supply Schedule pharmaceutical prices, 1 Oct 2026; Japan MHLW NHI drug price list (injections), 14 Oct 2026; ECB April 2026 rates

GEHC is usually the cheapest in standard CT contrast. Omnipaque is the lowest-priced standard iodinated brand on the U.S. federal schedule at the 300 strength and on Japan's national list at 350, though the U.S. lead is narrow and depends on pack size. In MRI, Clariscan costs 10–40% more than Guerbet's Dotarem in the U.S. but is the cheapest gadolinium agent in Japan. GEHC charges more for narrower agents such as Optison and Visipaque. These are federal ceilings and official reimbursement prices, and what hospitals actually pay after discounts will differ.

Medicare's rules have recently helped GEHC, paying separately for its DaTscan and Vizamyl brain tracers since 2025, and hurt PET specialists such as Lantheus and Telix once their temporary pass-through payments expired. Flyrcado is still on pass-through, at roughly $4,800 for a typical heart study, until early 2028, the same year GEHC wants it to reach $500M of revenue.

## Chapter four: a simpler company

Patient Care Solutions (monitors, anesthesia machines, infant care) shows the cost of old products most plainly, and it may be the simplest to fix. Revenue fell 13.5% organically in the second quarter of 2026 and the unit lost money, as parts shortages and end-of-life components on older lines caught up with it. Its new premium anesthesia system is still waiting for FDA clearance. In July GEHC put the unit under a strategic review that explicitly includes a sale. An update is expected around fourth-quarter results in February 2027.

A sale would leave GEHC as imaging plus the drugs that go into the scanners, a narrower company that's easier to explain. Keeping the unit means fixing supply first. Either way, the decision deals with the biggest single drag on the numbers. Without Patient Care, GEHC's adjusted EBIT margin over the twelve months to June was about 16.7%. That's level with Siemens Healthineers' 16.6% group margin, and about a point ahead once Siemens' tariff refund is taken out.

## Why we like it, and what we would pay

We like GE HealthCare for what it already owns. It's the only company that makes every major kind of scanner and every class of imaging drug, and its drug business earns a 29% segment margin. Service brings in a third of revenue at a 51% gross margin, which gives a turnaround time to work. And the fixes are in management's own hands: a lean operating system, two catch-up scanner platforms cleared this year, SOFIE, and a decision on its weakest unit.

We don't own it, and at today's price we wouldn't buy it. The Pure Value owner-earnings DCF runs to FY2035 at a 9% discount rate, with no growth after that. It values GEHC at $54.24 a share in the Base case, where margins reach the high teens, and $73.42 in the Bull case, where management's \~20% margin target is reached and held. The Bear case is $32.40\. At $70.23, the 20 October close, the stock trades 29% above the Base value and close to the Bull. To justify that price, the Base case would need owner earnings to grow about 2.6% a year forever after 2035\. The model's multiple-based cross-checks are kinder, with a Base sum-of-the-parts of $78.98 at the end of 2026, but they assume buyers keep paying today's peer and deal multiples. All things the same, we would heavily consider adding around $46, if the operating environment for GEHC changes for better or worse and impacts the potential entry we will give an update.

![](https://storage.ghost.io/c/48/60/4860aa23-9b17-4cca-9618-d0d2ab8af9fb/content/images/2026/10/image11-3.png)

Pure Value GEHC DCF workbook (15 October 2026 model): DCF value per share by case. GEHC share price: 20 October 2026 close (Fiscal.ai). The 2-to-1 set-up is the price at which upside to the Bull value is twice the downside to the Bear value.

## Disclosures and sources

This is research, not a recommendation to buy or sell, and not investment advice. Pure Value Capital holds no position in GEHC. Prices are 20 October 2026 closes. Statements attributed to management come from earnings calls and investor conferences. Channel-check views come from AlphaSense transcripts (June–September 2026) and are individual opinions. Revenue shares and growth rates are Pure Value calculations from company segment data at 2025 average exchange rates, and are partly estimated: Philips' 2019–2020 Diagnosis & Treatment sales are back-cast to its current segment basis, Mindray's 2019–2022 imaging revenue is scaled from its 2023 mix, and United Imaging's figures include radiotherapy. Twelve-month (TTM) figures are the latest fiscal year plus the latest year-to-date period, less the same period a year earlier, from company filings; they run to June 2026, except GE Aerospace and Pratt & Whitney, which run to September 2026\. GE Vernova's Power margin is segment EBITDA less depreciation and amortization, to compare with Siemens Energy's and Mitsubishi Heavy's profit measures.

GE HealthCare

- [Form 10 information statement, Dec 2022](https://www.sec.gov/Archives/edgar/data/1932393/000119312522297104/d379971dex991.htm?ref=purevalueideas.com)
- 10-K: [FY2022](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/gehc-20221231.htm?ref=purevalueideas.com), [FY2023](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000013/gehc-20231231.htm?ref=purevalueideas.com), [FY2024](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000005/gehc-20241231.htm?ref=purevalueideas.com), [FY2025](https://www.sec.gov/Archives/edgar/data/1932393/000193239326000007/gehc-20251231.htm?ref=purevalueideas.com)
- [2025 annual report](https://www.sec.gov/Archives/edgar/data/1932393/000193239326000025/a2025ars.pdf?ref=purevalueideas.com) and [2026 proxy statement](https://www.sec.gov/Archives/edgar/data/1932393/000193239326000021/gehc-20260318.htm?ref=purevalueideas.com)
- Results releases: [FY2023](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000012/release4q23earnings.htm?ref=purevalueideas.com), [FY2025](https://www.sec.gov/Archives/edgar/data/1932393/000193239326000006/release4q25earnings.htm?ref=purevalueideas.com), [Q2 2026](https://www.sec.gov/Archives/edgar/data/1932393/000193239326000045/release2q26earnings.htm?ref=purevalueideas.com)
- [2024 Investor Day](https://www.gehealthcare.com/en/insights/article/delivering-precision-care-through-innovation-ge-healthcares-2024-investor-day?ref=purevalueideas.com)
- Product releases: [Photonova Spectra FDA clearance](https://investor.gehealthcare.com/news-releases/news-release-details/ge-healthcares-photonova-spectra-photon-counting-ct-receives-fda?ref=purevalueideas.com), [SIGNA MRI with Freelium](https://www.gehealthcare.com/en/about/newsroom/press-releases/ge-healthcare-achieves-mri-portfolio-milestone-with-fda-clearances-for-next-generation-signa-mri-technology-designed-to-enhance-precision-imaging-and-clinical-efficiency?ref=purevalueideas.com), [Omni 128cm CE mark](https://www.businesswire.com/news/home/20251128007885/en?ref=purevalueideas.com), [Allia IGS Pulse](https://www.gehealthcare.com/en/about/newsroom/press-releases/ge-healthcare-receives-fda-clearance-of-allia-igs-pulse-image-guided-systems?ref=purevalueideas.com), [Vivid Pioneer](https://investor.gehealthcare.com/news-releases/news-release-details/ge-healthcare-unveils-vivid-pioneer-its-most-advanced-ai-powered?ref=purevalueideas.com), [Elekta collaboration](https://investor.gehealthcare.com/news-releases/news-release-details/ge-healthcare-elekta-collaborate-expand-access-precision?ref=purevalueideas.com)
- [SOFIE Biosciences acquisition, 5 Oct 2026](https://www.gehealthcare.com/en-us/about/newsroom/press-releases/ge-healthcare-to-acquire-sofie-biosciences-establishing-a-final-mile-footprint-for-pet-radiopharmaceutical-supply-in-the-us.html?ref=purevalueideas.com)
- Pure Value GEHC DCF workbook (15 October 2026 model)
- Second-quarter 10-Qs: [2025](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000049/gehc-20250630.htm?ref=purevalueideas.com) and [2026](https://www.sec.gov/Archives/edgar/data/1932393/000193239326000046/gehc-20260630.htm?ref=purevalueideas.com) (segment revenue, six months)
- [Segment history recast for the combined imaging and ultrasound segment](https://www.sec.gov/Archives/edgar/data/1932393/000193239326000047/gehcex99ais.htm?ref=purevalueideas.com) (8-K, July 2026)
- Product pages: [contrast media](https://www.gehealthcare.com/en-us/products/contrast-media?ref=purevalueideas.com), [molecular imaging agents](https://www.gehealthcare.com/en-us/products/molecular-imaging-agents?ref=purevalueideas.com); [SNMMI 2026 release](https://www.gehealthcare.com/en-us/about/newsroom/press-releases/ge-healthcare-focuses-on-expanding-access-to-nuclear-medicine-through-ai-radiopharmaceutical-and-imaging-innovations?ref=purevalueideas.com) (Omni Legend, StarGuide, cyclotrons); [MIM theranostics dosimetry clearance](https://www.gehealthcare.com/en-us/about/newsroom/press-releases/ge-healthcares-mim-software-announces-fda-clearance-of-monte-carlo-dosimetry-for-theranostics?ref=purevalueideas.com)
- [LOGIQ Focus launch](https://www.gehealthcare.com/en-us/about/newsroom/press-releases/ge-healthcare-expands-general-imaging-ultrasound-portfolio-with-logiq-focus-elevating-everyday-ultrasound-performance?ref=purevalueideas.com), 19 October 2026
- [Intelerad acquisition announcement](https://www.gehealthcare.com/en/about/newsroom/press-releases/ge-healthcare-to-acquire-intelerad-advancing-cloud-enabled-enterprise-imaging-across-care-settings?ref=purevalueideas.com), 20 November 2025
- [Investopedia, GE HealthCare Q1 2024 earnings preview](https://www.investopedia.com/ge-healthcare-q1-2024-earnings-preview-8638024?ref=purevalueideas.com)

GE siblings and their rivals

- GE Aerospace results: [FY2024](https://www.sec.gov/Archives/edgar/data/40545/000004054525000009/ge4q2024earningsrelease.htm?ref=purevalueideas.com), [FY2025](https://www.sec.gov/Archives/edgar/data/40545/000004054526000005/ge4q2025earningsrelease.htm?ref=purevalueideas.com)
- GE Vernova results: [FY2024](https://www.sec.gov/Archives/edgar/data/1996810/000199681025000004/gev4q2024earningsrelease.htm?ref=purevalueideas.com), [FY2025](https://www.sec.gov/Archives/edgar/data/1996810/000199681026000012/gevpressrelease4q25.htm?ref=purevalueideas.com), [Q2 2026](https://www.sec.gov/Archives/edgar/data/0001996810/000199681026000147/gevpressrelease2q26.htm?ref=purevalueideas.com)
- [RTX 2025 results (Pratt & Whitney)](https://www.sec.gov/Archives/edgar/data/101829/000010182926000003/a2026-01x278xkerexhibit99.htm?ref=purevalueideas.com) and [Rolls-Royce 2025 results](https://www.rolls-royce.com/media/press-releases/2026/26-02-2026-rr-holdings-plc-2025-full-year-results.aspx?ref=purevalueideas.com)
- GE Vernova [2025 Form 10-K](https://www.sec.gov/Archives/edgar/data/1996810/000199681026000015/gev-20251231.htm?ref=purevalueideas.com) (Note 24: Power segment EBITDA and depreciation; gas turbine orders in MD&A)
- Siemens Energy earnings releases: [Q4 FY2025](https://assets.siemens-energy.com/dam/b17980ef-1d11-4d4a-8c24-b394012dd9f4/2025-11-13%5FEarnings-Release-Q4-FY25-pdf%5FOriginal%20file.pdf?ref=purevalueideas.com) and [Q4 FY2024](https://assets.siemens-energy.com/dam/ed099e7a-c429-46b9-8e57-b2260127e834/Earnings-Release-Q4%5FEN%5Ffinal-pdf%5FOriginal%20file.pdf?ref=purevalueideas.com) (Gas Services profit before special items; fiscal years to September)
- Mitsubishi Heavy Industries results presentations: [FY2023](https://www.mhi.com/finance/library/result/pdf/fy20234q/presentation.pdf?ref=purevalueideas.com) and [FY2025](https://www.mhi.com/finance/library/result/pdf/fy20254q/presentation.pdf?ref=purevalueideas.com) (Energy Systems business profit; fiscal years to March)
- [GE Aerospace Q3 2026 results](https://www.sec.gov/Archives/edgar/data/40545/000004054526000063/ge3q2026earningsrelease.htm?ref=purevalueideas.com) and [RTX Q3 2026 results](https://www.sec.gov/Archives/edgar/data/101829/000010182926000030/a2026-10x208xkerexhibit99.htm?ref=purevalueideas.com), 20 October 2026
- GE Vernova [Q2 2026 Form 10-Q](https://www.sec.gov/Archives/edgar/data/1996810/000199681026000148/gev-20260630.htm?ref=purevalueideas.com) and [business-unit realignment supplement](https://www.gevernova.com/sites/default/files/gev%5Fbusiness%5Funit%5Frealignment%5Ffinancial%5Fsupplement%5F04222026.xlsx?ref=purevalueideas.com), April 2026
- [Siemens Energy Q3 FY2026 earnings release](https://assets.siemens-energy.com/dam/30018eed-275d-4e73-811e-b49d004cdc3d/2026-08-05-Earnings%5FRelease%5FQ3%5FFY26%5FEN-pdf%5FOriginal%20file.pdf?ref=purevalueideas.com) and [Mitsubishi Heavy Q1 FY2026 presentation](https://www.mhi.com/finance/library/result/pdf/fy20261q/presentation.pdf?ref=purevalueideas.com)

Siemens Healthineers

- Annual reports: [FY2019](https://corporate.webassets.siemens-healthineers.com/1800000006835562/383ab5036ed8/1800000006835562-12e08501046c-Siemens-Healthineers-Annual-Report-2019.pdf?ref=purevalueideas.com), [FY2020](https://corporate.webassets.siemens-healthineers.com/180f4f3673c1bef8/42315c736d84/180f4f3673c1bef8-747507c6608d-Siemens%5FHealthineers-%5FAnnual-%5FReport%5F2020.pdf?ref=purevalueideas.com), [FY2021](https://corporate.webassets.siemens-healthineers.com/df1896911b345f04/bc8ba64c5954/Siemens%5FHealthineers%5FAnnual-Report%5F2021.pdf?ref=purevalueideas.com), [FY2022](https://corporate.webassets.siemens-healthineers.com/df8210151cd8d47a/08fb7cbfa175/siemens-healthineers-ir-annual-report-2022.pdf?ref=purevalueideas.com), [FY2023](https://corporate.webassets.siemens-healthineers.com/f548fca6fac5ebe0/8bda062e9d1e/siemens-healthineers-ir-annual-report-2023.pdf?ref=purevalueideas.com), [FY2024](https://corporate.webassets.siemens-healthineers.com/427714ab59c7e09a/34f542dcc913/siemens-healthineers-ir-annual-report-2024.pdf?ref=purevalueideas.com), [FY2025](https://corporate.webassets.siemens-healthineers.com/a364b935102e7df5/d7fdacda458e/siemens-healthineers-ir-annual-report-2025.pdf?ref=purevalueideas.com)
- [Q3 FY2026 analyst presentation](https://corporate.webassets.siemens-healthineers.com/dcca776b3c3e4700/5549d89f5c9d/siemens-healthineers-Q3%5FFY2026%5FAnalyst-presentation.pdf?ref=purevalueideas.com) and [Q2 FY2026 call transcript](https://corporate.webassets.siemens-healthineers.com/73c0b165655db327/a9aaa85621f2/siemens-healthineers-Q2%5FFY2026%5FAnalyst-call-transcript.pdf?ref=purevalueideas.com)
- Product releases: [NAEOTOM Alpha FDA clearance](https://www.siemens-healthineers.com/press/releases/naeotomfda?ref=purevalueideas.com), [NAEOTOM family clearance](https://www.siemens-healthineers.com/en-us/press-room/press-releases/naeotom-family-fda-clearance?ref=purevalueideas.com), [NAEOTOM installed base](https://www.siemens-healthineers.com/jp/press-room/press-releases/pr-20250818-naeotom-alpha-class?ref=purevalueideas.com), [Magnetom Flow clearance](https://www.siemens-healthineers.com/en-us/press-room/press-releases/magnetom-flow-mr-platform-fda-clearance?ref=purevalueideas.com), [Biograph Vision Quadra clearance](https://www.siemens-healthineers.com/en-us/press-room/press-releases/fdaclearancebiographvisionquadra.html?ref=purevalueideas.com), [ARTIS clearances](https://www.siemens-healthineers.com/en-us/press-room/press-releases/artis-interventional-fda-clearance?ref=purevalueideas.com), [Varian closing](https://www.siemens-healthineers.com/press/releases/varian-closing?ref=purevalueideas.com)
- Siemens AG on the spin-off: [12 Nov 2025](https://assets.new.siemens.com/siemens/assets/api/uuid:5594e689-49ac-45a8-b559-c88af8e8bf70/HQCOPR202511127281EN.pdf?ref=purevalueideas.com), [17 Apr 2026](https://assets.new.siemens.com/siemens/assets/api/uuid:0b34deea-3a2a-48a1-b549-3242dc53016a/260417-press-release-en.pdf?ref=purevalueideas.com)
- Earnings releases: [Q2 FY2025](https://corporate.webassets.siemens-healthineers.com/fc25b12c62ae42f1/11ff94b61c14/siemens-healthineers-Q2%5FFY2025%5FEarnings-Release-and-Financial-Results.pdf?ref=purevalueideas.com), [Q3 FY2025](https://corporate.webassets.siemens-healthineers.com/0eb4ddc001f51f49/a383dfb48c5f/siemens-healthineers-Q3%5FFY2025%5FEarnings-Release-and-Financial-Results.pdf?ref=purevalueideas.com), [Q2 FY2026](https://corporate.webassets.siemens-healthineers.com/f973516aefed9689/c59e0c690a69/siemens-healthineers-Q2%5FFY2026%5FEarnings-Release-and-Financial-Results..pdf?ref=purevalueideas.com), [Q3 FY2026](https://corporate.webassets.siemens-healthineers.com/2637d4a46dbcd161/a3335cc16ed1/siemens-healthineers-Q3%5FFY2026%5FEarnings-Release-and-Financial-Results.pdf?ref=purevalueideas.com) (segment external revenue)
- [Q3 FY2026 earnings release](https://corporate.webassets.siemens-healthineers.com/2637d4a46dbcd161/a3335cc16ed1/siemens-healthineers-Q3%5FFY2026%5FEarnings-Release-and-Financial-Results.pdf?ref=purevalueideas.com) (Imaging segment, new basis)
- Radiopharma: [network page](https://www.siemens-healthineers.com/en-us/molecular-imaging/radiopharma?ref=purevalueideas.com) and [rebranding release, Nov 2025](https://www.siemens-healthineers.com/en-us/press-room/press-releases/radiopharma-rebranding?ref=purevalueideas.com)
- [Ultrasound refocus on procedural imaging](https://www.siemens-healthineers.com/press/releases/ultrasound?ref=purevalueideas.com), 12 October 2026

Philips

- Form 20-F: [2020](https://www.sec.gov/Archives/edgar/data/313216/000031321621000008/phg-20201231.htm?ref=purevalueideas.com), [2021](https://www.sec.gov/Archives/edgar/data/313216/000031321622000008/phg-20211231.htm?ref=purevalueideas.com), [2022](https://www.sec.gov/Archives/edgar/data/313216/000031321623000005/phg-20221231.htm?ref=purevalueideas.com), [2023](https://www.sec.gov/Archives/edgar/data/313216/000031321624000003/phg-20231231.htm?ref=purevalueideas.com), [2024](https://www.sec.gov/Archives/edgar/data/313216/000031321625000009/phg-20241231.htm?ref=purevalueideas.com), [2025](https://www.sec.gov/Archives/edgar/data/313216/000162828026009470/phg-20251231.htm?ref=purevalueideas.com)
- [Annual Report 2025](https://www.results.philips.com/app/uploads/2026/04/PhilipsFullAnnualReport2025-English.pdf?ref=purevalueideas.com), [Q2 2026 report (6-K)](https://www.sec.gov/Archives/edgar/data/0000313216/000162828026049913/a2026q2-philipsquarterlyen.htm?ref=purevalueideas.com)
- Capital Markets Day, Feb 2026: [transcript](https://www.philips.com/c-dam/corporate/about-philips/investors/calendar/2026/CMD%5F2026%5FTranscript.pdf?ref=purevalueideas.com), [Diagnosis & Treatment presentation](https://www.philips.com/c-dam/corporate/about-philips/investors/calendar/2026/3%5F-%5FDiagnosis%5Fand%5FTreatment.pdf?ref=purevalueideas.com)
- Respironics: [consent decree, Apr 2024](https://www.philips.com/a-w/about/news/archive/standard/news/press/2024/philips-respironics-reaches-agreement-with-us-government-on-a-consent-decree-creating-a-clear-path-forward.html?ref=purevalueideas.com), [Q1 2024 results (settlement)](https://www.philips.com/a-w/about/news/archive/corpcomms/news/press/2024/philips-first-quarter-results-2024.html?ref=purevalueideas.com)
- [BlueSeal installations, Mar 2026](https://www.philips.de/about/news-and-insights/press-release/premiere-in-europa-philips-stellt-weltweit-ersten-3-0t-mrt-mit-heliumfreiem-betrieb-vor?ref=purevalueideas.com)
- [Q2 2025 report (6-K)](https://www.sec.gov/Archives/edgar/data/313216/000031321625000029/a20250729q2-philipsquarter.htm?ref=purevalueideas.com) (Diagnosis & Treatment sales, January–June)

United Imaging

- [STAR Market prospectus, Aug 2022](http://static.cninfo.com.cn/finalpage/2022-08-16/1214298793.PDF?ref=purevalueideas.com)
- Annual reports: [2022](http://static.cninfo.com.cn/finalpage/2023-04-28/1216671621.PDF?ref=purevalueideas.com), [2023](http://static.cninfo.com.cn/finalpage/2024-04-27/1219885630.PDF?ref=purevalueideas.com), [2024](http://static.cninfo.com.cn/finalpage/2025-04-29/1223362977.PDF?ref=purevalueideas.com), [2025](https://static.cninfo.com.cn/finalpage/2026-04-29/1225233728.PDF?ref=purevalueideas.com)
- Interim reports: [1H25](http://static.cninfo.com.cn/finalpage/2025-08-30/1224621940.PDF?ref=purevalueideas.com), [1H26](http://static.cninfo.com.cn/finalpage/2026-08-20/1225481984.PDF?ref=purevalueideas.com)

Mindray

- Annual reports: [2019](http://static.cninfo.com.cn/finalpage/2020-04-02/1207447279.PDF?ref=purevalueideas.com), [2020](http://static.cninfo.com.cn/finalpage/2021-04-29/1209846282.PDF?ref=purevalueideas.com), [2021](http://static.cninfo.com.cn/finalpage/2022-04-20/1212976151.PDF?ref=purevalueideas.com), [2022](http://static.cninfo.com.cn/finalpage/2023-04-28/1216645583.PDF?ref=purevalueideas.com), [2023](http://static.cninfo.com.cn/finalpage/2024-04-27/1219856065.PDF?ref=purevalueideas.com), [2024](http://static.cninfo.com.cn/finalpage/2025-04-29/1223371173.PDF?ref=purevalueideas.com), [2025](https://static.cninfo.com.cn/finalpage/2026-03-31/1225059012.PDF?ref=purevalueideas.com)
- Interim reports: [1H25](http://static.cninfo.com.cn/finalpage/2025-08-28/1224595033.PDF?ref=purevalueideas.com), [1H26](http://static.cninfo.com.cn/finalpage/2026-08-29/1225529856.PDF?ref=purevalueideas.com)
- [HKEX Application Proof, May 2026](https://www1.hkexnews.hk/app/sehk/2026/108529/documents/sehk26051101259.pdf?ref=purevalueideas.com) (Frost & Sullivan market rankings)

Imaging-drug peers and prices

- [Lantheus 2025 Form 10-K](https://www.sec.gov/Archives/edgar/data/1521036/000119312526073498/lnth-20251231.htm?ref=purevalueideas.com) and [Q4 2025 results](https://www.sec.gov/Archives/edgar/data/1521036/000119312526073439/lnth-ex99%5F1.htm?ref=purevalueideas.com)
- [Telix 2025 Form 20-F](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm?ref=purevalueideas.com)
- [Guerbet 2025 Universal Registration Document](https://www.guerbet.com/sites/default/files/2026-04/guerbet%5Fdeu-uk%5F2025%5Fmel.pdf?ref=purevalueideas.com)
- [China Isotope & Radiation 2025 annual results](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0327/2026032704522.pdf?ref=purevalueideas.com) (HKEX)
- CMS [OPPS Addendum B](https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/addendum-a-b-updates?ref=purevalueideas.com), October 2023 to October 2026, and [Part B ASP pricing files](https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files?ref=purevalueideas.com)
- [VA Federal Supply Schedule pharmaceutical prices](https://department.va.gov/procurement-acquisition-and-logistics/wp-content/uploads/sites/56/2026/10/TPharmPrices2026-10-01.xlsx?ref=purevalueideas.com), 1 October 2026
- Lantheus [Q2 2026 results](https://www.sec.gov/Archives/edgar/data/1521036/000119312526336771/lnth-ex99%5F1.htm?ref=purevalueideas.com), [Q2 2026 Form 10-Q](https://www.sec.gov/Archives/edgar/data/1521036/000119312526336795/lnth-20260630.htm?ref=purevalueideas.com) and [Curium merger announcement](https://www.sec.gov/Archives/edgar/data/0001521036/000119312526329622/d148563dex991.htm?ref=purevalueideas.com), 3 August 2026
- [Telix H1 2026 report](https://www.sec.gov/Archives/edgar/data/2007191/000162828026058126/?ref=purevalueideas.com) (6-K), [Guerbet 2026 half-year report](https://www.guerbet.com/sites/default/files/2026-10/guerbet%5Fhalf-year-financial-report-2026.pdf?ref=purevalueideas.com), [China Isotope & Radiation 2026 interim results](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0828/2026082803670.pdf?ref=purevalueideas.com) (HKEX)
- Integration map: [Bayer Annual Report 2025](https://reports.bayer.com/annual-report-2025/en/%5Fassets/downloads/management-report-bayer-ar25.pdf?ref=purevalueideas.com), [Bracco portfolio](https://www.bracco.com/en-us/our-portfolio?ref=purevalueideas.com), Curium [products](https://www.curiumpharma.com/healthcare-professionals/product-portfolio/?ref=purevalueideas.com) and [locations](https://www.curiumpharma.com/about/locations/?ref=purevalueideas.com), [Cardinal Health FY2026 Form 10-K](https://www.sec.gov/Archives/edgar/data/721371/000072137126000038/cah-20260630.htm?ref=purevalueideas.com) and [theranostics release](https://newsroom.cardinalhealth.com/Center-for-Theranostics-Advancement-Shaping-the-future-of-precision-medicine?ref=purevalueideas.com), [Canon Annual Report 2025](https://global.canon/en/ir/annual/canon-annual-report-2025.pdf?ref=purevalueideas.com)
- Japan's [national health insurance drug price list, injections](https://www.mhlw.go.jp/topics/2026/04/xls/tp20261014-01%5F02.xlsx?ref=purevalueideas.com) (MHLW), applicable 14 October 2026
- [Lantheus shareholder vote on the Curium merger](https://www.sec.gov/Archives/edgar/data/1521036/000119312526421732/d183496d8k.htm?ref=purevalueideas.com) (8-K, 14 October 2026) and [antitrust refiling](https://www.sec.gov/Archives/edgar/data/1521036/000119312526396654/d148743d8k.htm?ref=purevalueideas.com) (8-K, September 2026)
- [Telix and ITM merger announcement](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/telix-6ktelixanditmjoinfor.htm?ref=purevalueideas.com) (6-K, 21 September 2026)

Regulators and data

- [FDA 510(k) database](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ref=purevalueideas.com): K181479, K210611, K250436, K253779, K211591, K243523, K253520, K182938, K210262, K232344, K251169, K242231, K233673, K243376
- [FDA list of AI-enabled medical devices](https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices?ref=purevalueideas.com) (current as of 4 Sep 2026)
- [Federal Reserve G.5A annual exchange rates, 2025](https://www.federalreserve.gov/releases/g5a/current/default.htm)
- [CMS CY2027 outpatient proposed rule](https://www.govinfo.gov/content/pkg/FR-2026-07-07/pdf/2026-13656.pdf?ref=purevalueideas.com)
- Federal Reserve [G.5A annual exchange rates](https://www.federalreserve.gov/releases/g5a/), 2019–2024, and [H.10 daily rates](https://www.federalreserve.gov/releases/h10/hist/) for the euro and yuan (fiscal-year and half-year averages)
- [ECB reference exchange rates](https://data.ecb.europa.eu/data/datasets/EXR?ref=purevalueideas.com), monthly averages (twelve-month conversions and Japan prices)

Public tenders

- [Zhejiang Government Procurement Network](https://zfcg.czt.zj.gov.cn/?ref=purevalueideas.com) award notices for 3.0T MRI, CT and ultrasound, Aug 2025–Oct 2026 (winning brand, model and unit price)
- EU Tenders Electronic Daily, Polish MRI award notices: [Kraków, Aug 2025](https://ted.europa.eu/en/notice/545438-2025?ref=purevalueideas.com), [Gniezno, Nov 2025](https://ted.europa.eu/en/notice/726658-2025?ref=purevalueideas.com), [Pabianice, Dec 2025](https://ted.europa.eu/en/notice/801102-2025?ref=purevalueideas.com), [Wrocław, Apr 2026](https://ted.europa.eu/en/notice/249284-2026?ref=purevalueideas.com), [Kalisz, May 2026](https://ted.europa.eu/en/notice/302738-2026?ref=purevalueideas.com)
- [Consip](https://www.consip.it/?ref=purevalueideas.com), Italy's national purchasing agency: framework tenders [ID 2785, 3-tesla MRI](https://www.consip.it/bandi/aq-tomografi-a-risonanza-magnetica-rm-3-tesla-ed-1?ref=purevalueideas.com) and [ID 2784, CT for advanced applications](https://www.consip.it/bandi/aq-apparecchiature-di-diagnostica-per-immagini-di-alta-fascia-tomografi-computerizzati-tc-ed-1?ref=purevalueideas.com): each supplier's signed framework agreement with its economic offer, the tender rules (capitolato d'oneri) and the award notices of Sep 2025
- [Federal Procurement Data System](https://www.fpds.gov/?ref=purevalueideas.com) orders: GE Revolution Ascend [36A79724N0386](https://www.fpds.gov/ezsearch/search.do?s=FPDS&indexName=awardfull&templateName=1.5.3&q=36A79724N0386&ref=purevalueideas.com), [36A79724N0263](https://www.fpds.gov/ezsearch/search.do?s=FPDS&indexName=awardfull&templateName=1.5.3&q=36A79724N0263&ref=purevalueideas.com), [SPE2D123F0256](https://www.fpds.gov/ezsearch/search.do?s=FPDS&indexName=awardfull&templateName=1.5.3&q=SPE2D123F0256&ref=purevalueideas.com); Siemens SOMATOM X.cite and go.Top [36A79724F0221](https://www.fpds.gov/ezsearch/search.do?s=FPDS&indexName=awardfull&templateName=1.5.3&q=36A79724F0221&ref=purevalueideas.com), [36A79724F0222](https://www.fpds.gov/ezsearch/search.do?s=FPDS&indexName=awardfull&templateName=1.5.3&q=36A79724F0222&ref=purevalueideas.com), [36A79723F0201](https://www.fpds.gov/ezsearch/search.do?s=FPDS&indexName=awardfull&templateName=1.5.3&q=36A79723F0201&ref=purevalueideas.com), [36A79724F0259](https://www.fpds.gov/ezsearch/search.do?s=FPDS&indexName=awardfull&templateName=1.5.3&q=36A79724F0259&ref=purevalueideas.com)
- [EU Tenders Electronic Daily](https://ted.europa.eu/?ref=purevalueideas.com) award notices for 3-tesla MRI and photon-counting CT, Jan 2023–Oct 2026, retrieved through the TED Search API
- Other national and regional procurement records: [Shanghai Government Procurement Network](https://www.zfcg.sh.gov.cn/?ref=purevalueideas.com) award notices; Brazil [Compras.gov.br open data](https://dadosabertos.compras.gov.br/?ref=purevalueideas.com) price module and [PNCP](https://pncp.gov.br/?ref=purevalueideas.com); [U.K. Contracts Finder](https://www.contractsfinder.service.gov.uk/?ref=purevalueideas.com); Indonesia Ministry of Health [IHSS contract award notices](https://kemkes.go.id/ihss?ref=purevalueideas.com) (MRI and CT, 2025); Japan Cabinet Secretariat [government procurement award data](https://www.cas.go.jp/jp/seisaku/chotatsu/07tyoutasu/rakusatsu/3%5Firyou/pdf/415.pdf?ref=purevalueideas.com); Ukraine [Prozorro](https://prozorro.gov.ua/?ref=purevalueideas.com); Colombia [SECOP II](https://community.secop.gov.co/?ref=purevalueideas.com)
- Exchange rates for tender prices: [ECB reference rates](https://data.ecb.europa.eu/?ref=purevalueideas.com), monthly averages; [National Bank of Ukraine](https://bank.gov.ua/?ref=purevalueideas.com) and [Banco de la República TRM](https://www.datos.gov.co/resource/32sa-8pi3.json?ref=purevalueideas.com) daily rates

Transcripts

- GEHC earnings calls and conference appearances (BofA May, Jefferies June, Wells Fargo September 2026); channel checks via expert calls